Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Infectious Disease Therapeutics Market Revenue Outlook: What CAGR Is Expected Through 2030?
The infectious disease therapeutics market size has grown strongly in recent years. It will grow from $150.6 billion in 2025 to $160.84 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to high global burden of infectious diseases, widespread use of antibiotics and antivirals, government immunization programs, growth of pharmaceutical manufacturing capacity, increased funding for infectious disease research.
The infectious disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $200.87 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rising antimicrobial resistance rates, increasing frequency of infectious disease outbreaks, expansion of global vaccination coverage, growing demand for novel antiviral therapies, stronger public health preparedness initiatives. Major trends in the forecast period include rising focus on antimicrobial resistance management, increasing development of broad-spectrum therapeutics, growing adoption of combination drug therapies, expansion of rapid-response therapeutics for outbreaks, increased investment in vaccine research and stockpiling.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15594&type=smp
Infectious Disease Therapeutics Market Growth Drivers: What Factors Are Accelerating Expansion?
The rising prevalence of infectious diseases is expected to propel the growth of the infectious disease therapeutics market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, parasites, or prions. The rising infectious diseases are due to several key factors such as climate change and environmental disruption, antimicrobial resistance, weakened immune systems, increasing interactions with animals, and ecological disturbances. Infectious disease therapeutics play a vital role in treating infections, reducing morbidity and mortality, and controlling the spread of communicable diseases within communities and across populations. For instance, in October 2023, according to the National Health Service (NHS) England, a UK-based government department, in 2022/23, hospitals reported 147,285 admissions with a primary diagnosis of urinary tract infection (UTI). Patients aged over 65 represented 56% of these cases, amounting to 82,392 admissions. The 80–84 age group had the highest number of admissions, with 17,280 cases. Therefore, the rising prevalence of infectious diseases drives the infectious disease therapeutics market.
Infectious Disease Therapeutics Market Segmentation And Category Breakdown
The infectious disease therapeutics market covered in this report is segmented –
1) By Type: Drugs, Vaccines
2) By Disease: Tuberculosis, HIV/AIDS, Influenza, Hepatitis, Other Diseases
3) By End-User: Hospitals And Clinics, Retail Pharmacies, Research Organizations, Other End Users
Subsegments:
1) By Drugs: Antibiotics, Antivirals, Antifungals, Antiparasitics, Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)
2) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, Mrna Vaccines, Dna Vaccines, Toxoid Vaccines
Infectious Disease Therapeutics Market Trends: What Is Shaping Future Industry Growth?
Major companies operating in the infectious disease therapeutics market are focusing on incorporating multispecific antibody platforms such as the multispecific therapeutic antibody reactor (MSTAR) to enhance efficacy, broaden protection, and strengthen responsiveness to emerging viral threats. Multispecific therapeutic antibody reactor (MSTAR) is an advanced multispecific antibody technology that combines several independent binding regions into a single therapeutic molecule, enabling capabilities such as broad viral neutralization, simultaneous targeting of multiple epitopes, and rapid adaptation to new variants. For instance, in September 2023, ModeX Therapeutics Inc, a US-based clinical stage biopharmaceutical company, secured a contract from the Biomedical Advanced Research and Development Authority to advance its multispecific antibody candidates designed for the treatment and prevention of viral infectious diseases including COVID 19 and influenza, featuring broad activity against circulating viral strains, potential compatibility with gene based delivery using mRNA or DNA vectors, and a multi binding site architecture. This multispecific antibody approach improves therapeutic outcomes by shortening development timelines, expanding protective coverage, and reducing the complexity associated with combination biologic treatments.
Infectious Disease Therapeutics Market Competitive Analysis Of Major Industry Participants
Major companies operating in the infectious disease therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, AstraZeneca, Novartis International AG, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceuticals, Moderna Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioCryst Pharmaceuticals Inc.
Access The Complete Infectious Disease Therapeutics Market Report:
Infectious Disease Therapeutics Market Geographic Distribution And Regional Opportunities
North Americawas the largest region in the infectious disease therapeutics market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model